Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity

J Infect Chemother. 2022 Jul;28(7):971-974. doi: 10.1016/j.jiac.2022.02.006. Epub 2022 Feb 10.

Abstract

Corticosteroids are widely used to treat severe COVID-19, but in immunocompromised individuals, who are susceptible to persistent infection, long term corticosteroid use may delay viral clearance. We present a case of prolonged SARS-CoV-2 infection in a man with significantly impaired B-cell immunity due to non-Hodgkin lymphoma which had been treated with rituximab. SARS-CoV-2 shedding persisted, despite treatment with remdesivir. Viral sequencing confirmed the persistence of the same viral strain, ruling out the possibility of reinfection. Although SARS-CoV-2 IgG, IgA and IgM remained negative throughout the treatment period, after reduction of the corticosteroid dose, PCR became negative. Long-term corticosteroid treatment, especially in immunocompromised individuals, may result in suppression of cell-mediated immunity and prolonged SARS-CoV-2 infection.

Keywords: COVID-19; Corticosteroids; Immunocompromised; Rituximab; SARS-CoV-2 infection; Viral shedding.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Viral
  • COVID-19 Drug Treatment*
  • Humans
  • Immunocompromised Host
  • Male
  • Rituximab / adverse effects
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • Rituximab